Ismary Decastro, MD
Endocrinology, Diabetes & Metabolism · Savannah, GANPI 1962697730
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $135,262 of the $168,571 with a category attached, or 80.2%. Novo Nordisk accounts for 78.6% of it on its own, with 52 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 905 payments — averaging $186.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$132K
- Sanofi-aventis U.S. LLC$19K
- Amgen$4K
- Lilly USA, LLC$2K
- Globus Medical$1K
- Mannkind Corporation$1K
- plus $9K from 47 others
What the payments were for
- Speaking & faculty fees$135,26280%
- Travel & lodging$15,2509%
- Food & beverage$17,83511%
- Education$1640%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$57,767
- RYBELSUS$48,170
- SOLIQUA 100/33$12,541
- Tresiba$10,970
- TOUJEO$4,945
- TEPEZZA$1,508
- Prolia$800
- VuePoint$714
- XLIF$685
- AFREZZA$598
- EVENITY$220
- FARXIGA$212
- CeQur Simplicity$130
- MINIMED 780G$122
- DEXCOM G6 TRANSMITTER$115
- NEXLIZET$112
- NEXLETOL$112
- V-GO$109
How this compares
$168,571 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 295 | $394,242 |
| MounjaroTirzepatide | 221 | $261,377 |
| JardianceEmpagliflozin | 184 | $190,254 |
| TrulicityDulaglutide | 104 | $125,163 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 77 | $94,047 |
| FarxigaDapagliflozin Propanediol | 64 | $75,845 |
| Tresiba Flextouch U-200Insulin Degludec | 56 | $65,633 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $56,550 |
| RybelsusSemaglutide | 34 | $55,784 |
| Teriparatide | 16 | $48,789 |
| JanuviaSitagliptin Phosphate | 59 | $44,336 |
| Tresiba Flextouch U-100Insulin Degludec | 67 | $38,448 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $35,651 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $27,313 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $27,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $132,459 | $461,102353 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,511 | $393,032343 claims |
| Boehringer IngelheimJardiance | $472 | $190,254184 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $18,614 | $94,04777 claims |
| AstraZenecaFarxiga | $1,080 | $75,84564 claims |
| PfizerGenotropin | $40 | $23,02727 claims |
| AbbVieSynthroid, Armour Thyroid | $296 | $22,170258 claims |
| AmgenProlia | $3,869 | $20,90012 claims |
| IBSA Pharma Inc.Tirosint, Tirosint-Sol | $241 | $16,62964 claims |
| Antares Pharma, Inc.Xyosted | $199 | $15,89922 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $306 | $3,786390 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Savannah
- Kaveh EhsanipoorSavannah$76K
- Joseph DehavenSavannah$58K
- Carolyn NelsonSavannah$25K
- James StoeverSavannah$11K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.